Kazia Therapeutics (KZIA) Total Current Liabilities (2009 - 2025)
Kazia Therapeutics' (KZIA) quarterly Total Current Liabilities came in at $16.0 million in Q4 2025, up 48.2% YoY from $10.8 million in Q4 2024, and up 77.81% on a QoQ basis from $9.0 million in Q2 2025.
Kazia Therapeutics (KZIA) Total Current Liabilities (2009 - 2025) Analysis & Trends
Kazia Therapeutics (KZIA) has 17 years of Total Current Liabilities data on file, last reported at $16.0 million in Q4 2025.
- Quarterly Total Current Liabilities rose 48.2% year-over-year to $16.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $16.0 million (up 48.2% YoY) and the FY2025 annual result came in at $9.0 million, down 47.06% from the prior year.
- Total Current Liabilities advanced to $16.0 million in Q4 2025, from $9.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $17.0 million in Q2 2024 to a low of $3.7 million in Q4 2022.
- A 5-year average of $8.6 million and a median of $6.9 million in 2021 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 236.24% — and 2025, when it slumped 47.06%.
- Tracing KZIA's Total Current Liabilities over 5 years: stood at $5.5 million in 2021, then sank by 33.7% to $3.7 million in 2022, then surged by 101.2% to $7.4 million in 2023, then jumped by 46.33% to $10.8 million in 2024, then soared by 48.2% to $16.0 million in 2025.
- The last three Total Current Liabilities figures came in at $16.0 million (Q4 2025), $9.0 million (Q2 2025), and $10.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Kazia Therapeutics | 4.22 Bn | 4.22 Bn | - | 16.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.00 Mn |
| Jun 30, 2025 | 9.00 Mn |
| Dec 31, 2024 | 10.80 Mn |
| Jun 30, 2024 | 17.00 Mn |
| Dec 31, 2023 | 7.38 Mn |
| Jun 30, 2023 | 5.06 Mn |
| Dec 31, 2022 | 3.67 Mn |
| Jun 30, 2022 | 4.82 Mn |
| Dec 31, 2021 | 5.53 Mn |
| Jun 30, 2021 | 6.41 Mn |
| Dec 31, 2020 | 1.99 Mn |
| Jun 30, 2020 | 3.32 Mn |
| Dec 31, 2019 | 2.11 Mn |
| Jun 30, 2019 | 1.33 Mn |
| Dec 31, 2018 | 1.74 Mn |
| Jun 30, 2018 | 2.94 Mn |
| Jun 30, 2017 | 4.04 Mn |
| Dec 31, 2016 | 5.29 Mn |
| Jun 30, 2016 | 4.02 Mn |
| Dec 31, 2015 | 1.28 Mn |